About The Author

Editorial & Columns

Filling a Whitespace: Merger of Dabur India and Sesa Care

June 4, 2025 | Dr. Anil Kumar Angrish | No Comments |

More

Editorial & Columns

FY25 Review: Profitability of Leading Pharma Companies in India

May 28, 2025 | Dr. Anil Kumar Angrish | No Comments |

More

Editorial & Columns

Joint Ventures: Experience of Indian Pharmaceutical Companies

May 21, 2025 | Dr. Anil Kumar Angrish | No Comments |

More

Editorial & Columns

India–UK Free Trade Agreement-Data Exclusivity and Pharma Industry in India

May 15, 2025 | Dr. Anil Kumar Angrish | No Comments |

More

Editorial & Columns

Small Country, Big Concern for the US: Ireland’s Pharma Exports

May 5, 2025 | Dr. Anil Kumar Angrish | No Comments |

More

Editorial & Columns

Learning from the Longest Surviving Pharma Enterprise

April 28, 2025 | Dr. Anil Kumar Angrish | No Comments |

More

Editorial & Columns

China Plus One: India as a Fit Candidate in Pharmaceuticals

April 24, 2025 | Dr. Anil Kumar Angrish | No Comments |

More

Editorial & Columns

Factoring Inflation in Medicine Prices: Need for a Sectoral Index in India

April 15, 2025 | Dr. Anil Kumar Angrish | No Comments |

More

Editorial & Columns

FY24 Review: Profitability of select Pharmaceutical Companies in India

April 9, 2025 | Dr. Anil Kumar Angrish | No Comments |

More

Editorial & Columns

FY25: Deciphering Pharma Exports from India

April 2, 2025 | Dr. Anil Kumar Angrish | No Comments |

More